Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 4, 2008, Pages 563-568

  Ulak, Güner ^a   Mutlu, Oguz ^a   Akar, Füruzan Yildiz ^a   Komsuoǧlu, F Ipek ^a   Tanyeri, Pelin ^a   Erden, B Faruk ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Antidepressant; Forced swimming test; Nitric oxide; Rat; TRIM

Indexed keywords

1 (2 TRIFLUOROMETHYLPHENYL) IMIDAZOLE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; REBOXETINE; TIANEPTINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUOXETINE; IMIDAZOLES; MALE; MORPHOLINES; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SWIMMING; THIAZEPINES;

ANIMALIA; RATTUS;

EID: 48749127299     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.04.016     Document Type: Article

References (43)

1. Boothman L.J., Mitchell S.N., and Sharp T. Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. Neuropharmacology 50 (2006) 726-732
2. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19 (1995) 377-395
3. Carrodi H., and Fuxe K. The effects of imipramine on central monoamine neurones. J Pharm Pharmacol 20 (1968) 230-231
4. Connor T.J., Kelliher P., Harkin A., Kelly J.P., and Leonard B.E. Reboxetine attenuates forced swim test -induced behavioral and neurochemical alterations in the rat. Eur J Pharmacol 379 (1999) 125-133
5. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23 (2002) 238-245
6. Cryan J.F., Page M.E., and Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436 (2002) 197-205
7. Datla K.P., and Curzon G. Behavioural and neurochemical evidence for the decrease of brain extracellular 5-HT by the antidepressant drug tianeptine. Neuropharmacology 32 (1993) 839-845
8. Dhir A., and Kulkarni S.K. Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 80 (2007) 239-243
9. East S.J., and Garthwaite J. NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the L-arginine-nitric oxide pathway. Neurosci Lett 123 (1991) 17-19
10. Fattacini C.M., Bolanos-Jimenez F., Gozlan H., and Hamon M. Tianeptine stimulates uptake of 5-hydroxytryptamine in vivo in the rat brain. Neuropharmacology 29 (1990) 1-8
11. Felton T.M., Kang T.B., Hjorth S., and Auerbach S.B. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 297-305
12. File S.E., and Mabbutt P.S. Effects of tianeptine in animal models of anxiety and on learning and memory. Drug Dev Res 23 (1991) 47-56
13. Finkel M.S., Laghrissi-Thode F., Pollock B.G., and Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 32 (1996) 653-658
14. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14 (1991) 60-67
15. Ghasemi M., Sadeghipour H., Mosleh A., Sadeghipour H.R., Mani A.R., and Dehpour A.R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur Neuropsychopharmacol 18 (2008) 323-332
16. Goodnick P.J., and Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology. J Psychopharmacol 12 3suppl (1998) S5-S20
17. Handy R.L., Wallace P., Gaffen Z.A., Whitehead K.J., and Moore P.K. The antinociceptive effect of 1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. Br J Pharmacol 116 (1995) 2349-2350
18. Handy R.L., Harb H.L., Wallace P., Gaffen Z., Whitehead K.J., and Moore P.K. Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) in vitro: antinociceptive and cardiovascular effects. Br J Pharmacol 119 (1996) 423-431
19. Harkin A.J., Bruce K.H., Craft B., and Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice: 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 372 (1999) 207-213
20. Harkin A., Kelly J.P., McNamara M., Connor T.J., Dredge K., Redmond A., et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 364 (1999) 123-132
21. Harkin A., Connor T.J., Walsh M., St. Jonh N., and Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44 (2003) 616-623
22. Harkin A., Connor T.J., Burns M.P., and Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 14 4 (2004) 274-281
23. Kelly J.P., and Leonard B.E. The effect of tianeptine and sertraline in three animal models of depression. Neuropharmacology 33 (1994) 1011-1016
24. Kiss J.P. Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res Bull 52 (2000) 459-466
25. Lacroix P., Rocher N., and Deslandes A. Antidepressant effects of tianeptine, of its two enantiomers and its predominant metabolite in the learned helplessness test in rats. Eur Neuropsychopharmacol 6 Suppl.4 (1996) S4-S70
26. Maj J., Rogoz Z., Skuza G., and Sowinska H. The effects of CGP 37849 and CGP 39551 competitive NMDA receptor antagonists in the forced swimming test. Pol J Pharmacol Pharm 44 (1992) 337-346
27. Mennini T., Mocaer E., and Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmeidebergs Arch Pharmacol 336 (1987) 478-482
28. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43 (1991) 109-142
29. Nowakowska E., Kus K., Chodera A., and Rybakowski J. Behavioural effects of fluoxetine and tianeptine, two antidepressants with opposite action mechanisms, in rats. Arzneimittelforschung 50 1 (2000) 5-10
30. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatment. Nature 266 (1977) 730-732
31. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to anti-depressant treatments. Eur J Pharmacol 47 (1978) 379-391
32. Rogoz Z., Skuza G., Maj J., and Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42 (2002) 1024-1030
33. Tatarczynska E., Klodzinska A., Stachowicz K., and Chojnacka-Wojcik E. Effect of combined administration of 5HT1A or HT1B/1D receptor antagonists and antidepressants in the forced swimming test. Eur J Pharmacol 487 (2004) 133-142
34. Trullas R. Functional NMDA antagonists: a new class of antidepressant agents. In: Skolnick P. (Ed). Antidepressants, New Pharmacological Strategies (1997), Humana Pres, Totowa, NJ 103-124
35. Trullas R., and Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185 (1990) 1-10
36. Volke V., Wegener G., Bourin M., and Vasar E. Antidepressant-and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 140 (2003) 141-147
37. Wegener G., Volke V., and Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 130 (2000) 575-580
38. Wegener G., Volke V., Harvey B.H., and Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 959 (2003) 128-134
39. Wegener G., Bandpey Z., Heiberg I.L., Volke V., Trabace L., Rosenberg R., et al. Combined chronic treatment with citalopram and lithium does not modify the regional neurochemistry of nitric oxide in rats brain. J Physiol Pharmacol 55 3 (2004) 575-586
40. Wilde M.I., and Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 49 (1995) 411-439
41. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the Fourth Generation of Progress (1995), Raven Press, New York 921-931
42. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47 (2000) 818-829
43. Yildiz F., Erden B.F., Ulak G., Utkan T., and Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 149 (2000) 41-44